Herceptin now available for subcutaneous injection

A subcutaneous formulation of the breast cancer treatment Herceptin (trastuzumab) that significantly reduces administration time is now available.

HER2 status must be established before starting treatment with Herceptin
HER2 status must be established before starting treatment with Herceptin

Herceptin (trastuzumab) 600mg/5ml solution for subcutaneous injection reduces administration time to 2–5 minutes compared with the 30–90 minutes needed for intravenous infusion. In addition, the subcutaneous formulation is given in a fixed treatment regimen of 600mg every three weeks, in contrast to the dose for intravenous administration which must be calculated on the basis of body weight.

Breast cancer use only

The new formulation is licensed for use only in HER2-positive metastatic or early breast cancer. The intravenous preparation can also be used to treat HER2-positive metastatic gastric cancer within its licensed indication.

Non-inferior to iv injection

The open-label, phase 3 HannaH trial was conducted to establish the non-inferiority of subcutaneous injection to intravenous infusion for administration of trastuzumab. A total of 596 patients with HER2-positive operable, locally advanced or inflammatory breast cancer were randomly assigned to undergo eight cycles of neoadjuvant chemotherapy in combination with trastuzumab every three weeks given by either the intravenous or subcutaneous route.

Results showed that subcutaneous trastuzumab was non-inferior to intravenous trastuzumab, with comparable serum trough concentrations (measured at predose cycle 8 before surgery) and pathological complete response rates (45.4% and 40.7%, respectively).

View Herceptin drug record

Further Information: Roche

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases